Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Platelet polymorphism and coronary artery disease].

L Christiaens1, L Macchi, C Duplantier

  • 1Département médico-chirurgical de cardiologie, CHU Poitiers, 86021 Poitiers. l.christiaens@chu-poitiers.fr

Archives Des Maladies Du Coeur Et Des Vaisseaux
|May 10, 2002
PubMed
Summary

Genetic mutations in platelet glycoproteins (GPIIIa, GPIb, GPIa-IIa) are linked to arterial disease and heart attack risk, particularly in younger individuals. These findings may also predict response to antiplatelet medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality indicators for pharmacist follow-up of diabetes mellitus: A RAND-modified Delphi method.

International journal of clinical pharmacy·2025
Same author

Left atrial volume assessed by ECG-gated computed tomography: Variations according to age, gender and time during the cardiac cycle.

Diagnostic and interventional imaging·2018
Same author

Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine Arabinoside.

Leukemia & lymphoma·2016
Same author

Translocation t(12;13)(p13.3;q12.2) is Not Restricted to Lymphoid Malignancies; Report of a Further Case with Hypereosinophilia.

Leukemia & lymphoma·2016
Same author

Establishment of diagnostic reference levels in cardiac CT in France: a need for patient dose optimisation.

Radiation protection dosimetry·2014
Same author

[Thrombotic thrombocytopenic purpura: do not ignore cardiac involvement].

La Revue de medecine interne·2013

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Hematology

Context:

  • Platelet membrane glycoproteins play a crucial role in hemostasis and thrombosis.
  • Genetic variations in these glycoproteins have been investigated for their association with thrombotic arterial diseases.
  • Previous research has yielded controversial findings regarding these associations.

Purpose:

  • To review and synthesize the current understanding of platelet glycoprotein polymorphisms and their link to myocardial infarction and coronary artery disease.
  • To explore the specific roles of GPIIIa (including PLA2 polymorphism), GPIb, and GPIa-IIa complex polymorphisms.
  • To assess the implications of these genetic factors for individual sensitivity to antiplatelet therapies.

Summary:

  • Several platelet glycoprotein gene polymorphisms, including GPIIIa, GPIb, and GPIa-IIa, have been studied in relation to thrombotic arterial disease.

Related Experiment Videos

  • The PLA2 polymorphism of GPIIIa is a recognized risk factor for myocardial infarction in young smokers, but its general population impact is debated.
  • Other GPIb and GPIa-IIa polymorphisms may contribute to early coronary thrombotic events.
  • Investigating these polymorphisms offers insights into personalized antiplatelet treatment strategies.

    • Impact:

    • Clarifies the complex relationship between platelet gene variations and cardiovascular disease risk.
    • Highlights the potential of genetic markers for identifying individuals susceptible to thrombotic events.
    • Provides a basis for tailoring antiplatelet therapy based on individual genetic profiles, potentially improving treatment efficacy and reducing adverse events.